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IMPACT OF DIHYDROPYRROL DERIVATIVE ON THE NORMAL 
COLONIC MUCOSA OF DMH-INDUCED COLON CANCER RATS 
COMPARED WITH 5-FLUOROURACIL
H.M. Kuznietsova*, O.V. Ogloblya, V.K. Rybalchenko
Taras Shevchenko National University, Kyiv 01601, Ukraine
Aim: To compare the effects of cytostatic compound dihydropyrrol derivative (D1, 5-amyno-4-(1,3-benzothyazol-2-yl)-1-(3-
methoxyphenyl)-1,2-dihydro-3Н-pyrrol-3-one) and 5-fluorouracil (5-FU) on the normal colonic mucosa of tumor-bearing rats and 
to estimate the relationships between proliferation of normal colonic mucosa and tumor growth parameters. Methods: 1,2-dimethyl-
hydrazine (DMH) carcinogenic model was used. Male Wistar rats were treated by dimethylhydrazine (20 mg/kg of body weight (b.w.) 
weekly) for 20 weeks, by D1 (2.3 mg/kg of b.w. daily) for 7 or 27 weeks, and by 5-FU (45 mg/kg of b.w. weekly) for 7 weeks. The 
number of tumor and tumor total area in dissected colon, mitotic and crypt fission indices in surrounding colon mucosa were measured 
and correlations between these parameters were computed. Results: The number of tumor node and tumor total area under the influ-
ence of D1 and 5-FU were decreased by 40–54%. D1 administration has resulted in the more gentle effect on surrounding healthy 
colon mucosa comparing to 5-FU, particularly, on vascular bed and proliferative activity. The changes in colon mucosa proliferative 
activity correlate with tumor growth parameters depending on the action of D1 or 5-FU. Conclusions: D1 manifests the same antitu-
mor activity but less toxicity comparing to 5-FU that allow to suggest its possible use as an anticancer mean. Obtained correlations 
could be useful for better understanding of the processes preceeding the malignant transformation and their pharmaceutical correction.
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Cancer is a major public health problem in all coun-
tries [1]. Statistical data have shown that malignant neo-
plasia remain a second cause of disease-related deaths 
after cardiovascular diseases [2], but demonstrate the 
tendency to overtake it. In Ukraine, about 160,000 new 
cases of cancer are diagnosed annually [3]. Unfortu-
nately, conventional cytotoxic chemotherapy has high 
frequency and severity of adverse effects on the nor-
mal, actively proliferating tissues. This is the one of the 
main factors for choosing the proper chemotherapy 
and for outcomes of the therapeutical treatment [4, 5]. 
Therefore, the development of effective and selective 
anticancer drugs is a important and actual task. Tar-
geted therapeutic agents, e.g., protein kinase inhibitors, 
have a high specificity to malignant cells and low toxicity 
[6–9], but their influence on the organism had not been 
thoroughly studied. In particular, the information about 
histopathology of healthy tissues of the cancer patients 
is extremely scarce. So, the design, extensive in vivo 
testing and profound analysis of adverse effects of the 
novel targeted protein kinase inhibitors are warranted.
Dihydropyrrol derivates, synthesized as a novel 
tyrosine kinase ATP-binding site blockers [10], show 
in vitro cytostatic activity against the cell lines, such 
as HT29, HCT-15, and COLO-205 (colorectal cancer) 
[11] that suggests their potential anticancer activity. 
The current investigation was aimed to study the ef-
fects of dihydropyrrol derivative D1 on tumor growth 
and proliferative activity of surrounding mucosa 
in colorectal cancer bearing rats. For comparison, 
the effects of 5-fluorouracil (5-FU), a conventional 
therapeutic agent for colon cancer treatment [5,12], 
was concomitantly investigated.
MATERIALS AND METHODS
Animals. Sixty male Wistar rats weighing 120–
130 g were studied. Animals were kept in the standard 
vivarium conditions. All experimental procedures 
executed with animals were in compliance with the 
European Community Council Directive.
Chemicals. D1 (5-amyno-4-(1,3-benzothyazol-
2-yl)-1-(3-methoxyphenyl)-1,2-dihydro-3Н-pyrrol-
3-one) (Fig. 1) was synthesized as a protein tyrosine 
kinase inhibitor at the Department of Chemistry of the 
Taras Shevchenko National University of Kyiv [10]. 
Fig. 1. Dihydropyrrol derivative 5-amyno-4-(1,3-benzothyazol-
2-yl)-1-(3-methoxyphenyl)-1,2-dihydro-3Н-pyrrol-3-one
D1 has in vitro antiproliferative activity and low in vivo 
intestine toxicity [10, 13]. The agent was dissolved 
in vegetable oil containing 15% dimethylsulfoxide. Ani-
mals were treated by D1 at a dose of ≈ 2.3 mg/kg of body 
weight (b.w.) per os daily for 7 or 27 weeks. Saline solu-
tion of 5-FU (“Darnitsa”, Ukraine) was intraperitoneally 
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injected into animals at a dose of 45 mg/kg b.w. weekly 
for 7 weeks, as previously described [14]. 1,2-dime-
thylhydrazine (DMH) (Acros Organics, USA), a highly 
specific colorectal carcinogen in rodents, was dissolved 
immediately before use in saline solution adjusted 
to pH 6.5 with sodium hydroxide. To induce tumor de-
velopment, animals were subcutaneously injected with 
20 mg/kg b.w. DMH weekly for 20 weeks [15].
Experimental design. The rats were divided into 
6 groups: vehicle-treated control (group 1), DMH-
treated (group 2), DMH+D1 27-week-treated (group 
3), DMH+D1 7-week-treated (group 4), DMH+5-FU-
treated (group 5), DMH+D1+5-FU-treated (group 6) 
(Fig. 2). In groups 2–6, the rats were injected with 
20 mg/kg b.w. DMH weekly for 20 weeks, whereas, 
in the control group, the rats were similarly injected 
with the same volume of vehicle (0.1 ml). In group 
3, the rats also daily ingested 2.3 mg/kg b.w. D1 for 
27 weeks, whereas in groups 1–2, the rats daily inges-
ted the same volume of vehicle (0.1 ml) for 27 weeks. 
In groups 4–6, the weekly injections of 20 mg/kg b.w. 
DMH and the daily ingestions of 0.1 ml of vehicle solu-
tion for 20 weeks were followed by the daily ingestions 
of 2.3 mg/kg b.w. D1 (group 4), weekly injections 
of 45 mg/kg b.w. 5-FU (group 5), and by concomitant 
daily ingestions of 2.3 mg/kg b.w. D1 and weekly in-
jections of 45 mg/kg b.w. 5-FU (group 6), for 7 weeks 
(Fig. 2).
Fig. 2. Experimental protocol. Initially, 60 rats were divided 
into 6 groups (10 rats per group). Rats were treated with DMH 
(20 mg/kg) in 2–6 or the same volume of vehicle (0.1 ml) in 1, and 
with D1 (2.3 mg/kg) in 3 and the same volume of vehicle (0.1 ml) 
in others for 20 weeks. The intraperitoneal 5-FU injections 
(45 mg/kg) in 5–6 and D1 consumptions (2.3 mg/kg) in 3; 4; 6 for 
7 weeks conducted as a treatment procedure
Tissue preparation. After the treatments, the rats 
were sacrificed by cervical dislocation, the abdomen 
was opened and the entire gastrointestinal tract was 
removed. The colon samples were fixed for 14 days 
in neutral saline solution containing 10% formalin. 
Then, they were embedded into paraffin and sliced into 
5-μm sections, which were stained with hematoxylin-
eosine-orange [16] and examined under the light 
microscope. The tumor number per animal (Ntumor) and 
the area of tumors were measured from the color im-
ages using the image processing and analysis program 
WCIF ImageJ. The tumor total area per animal (Stumor) 
was calculated as a sum of the areas of all tumors 
in the colon. The mean tumor area represents the ratio 
of tumor total area over the total number of tumors. The 
colon samples with no tumors studied for detection 
of changes in the apparently healthy colon mucosa 
under the influence of the agents were examined 
under the light microscope. The mucosa thickness, 
the height and nuclei area of colonocytes and the 
area of the goblet cells were measured from the color 
microphotographs (magnification x400) using WCIF 
ImageJ software. The mitotic index (MI) in 300 colonic 
crypt epithelial cells per animal and crypt fission index 
(CFI) in 200 colon crypts per animal were calculated 
in the apparently healthy colon mucosa.
Statistical analysis was carried out using SPSS 
17.0 software for Windows. One-way ANOVA followed 
by the post-hoc Bonferroni’s test was employed to de-
termine statistical significance. Correlation analysis 
was conducted using Spearman rho correlation test. 
p < 0.05 was considered statistically significant.
RESULTS
Visual inspection of the test animals detected tumors 
in the downstream section of the colon, mainly of exo-
phytic type, which is consistent with published data [15]. 
Data for the tumor number, tumor mean and total area 
for all, exophytic (adenomas and hyperplastic polyps) 
and endophytic (adenocarcinomas) tumors showed 
that D1, 5-FU, and their combination D1+5-FU affect 
mainly the proliferation of exophytic tumors (Table 1).
Table 1. Tumor parameters for rats treated by D1, 5-FU and their com-
bination under DMH-induced carcinogenesis (27 weeks) (Mean ± SEM, 
n = 10)
DMH DMH + D1  (27 weeks)
DMH + D1  
(7 weeks)
DMH + 
5-FU
DMH + 
D1 + 
5-FU
All
Tumor number 
(Ntumor)
9.56 ± 
1.74
7.17 ± 
1.70*
5.60 ± 
1.27*
4.78 ± 
1.44*
5.20 ± 
1.71*
Tumor mean 
area, cm2
0.17 ± 
0.07
0.12 ± 
0.06
0.17 ± 
0.05
0.19 ± 
0.13
0.14 ± 
0.04
Tumor total area 
(Stumor), cm2
1.58 ± 
0.65
0.86 ± 
0.47*
0.94 ± 
0.40*
0.91 ± 
0.68*
0.73 ± 
0.20*
Exophytic Tumors
Tumor number 
(Ntumor)
9.00 ± 
1.53
6.50 ± 
2.23*
4.90 ± 
1.38*
4.44 ± 
1.42*
4.50 ± 
1.41*
Tumor mean 
area, cm2
0.12 ± 
0.03
0.11 ± 
0.06
0.10 ± 
0.02
0.10 ± 
0.04
0.12 ± 
0.04
Tumor total area 
(Stumor), cm2
1.03 ± 
0.28
0.56 ± 
0.37*
0.49 ± 
0.16*
0.46 ± 
0.21*
0.49 ± 
0.22*
Endophytic Tumors
Tumor number 
(Ntumor)
0.67 ± 
0.47
0.67 ± 
0.67
0.70 ± 
0.60
0.33 ± 
0.31
0.70 ± 
0.60
Tumor mean 
area, cm2
0.82 ± 
0.81
0.45 ± 
0.44
0.64 ± 
0.16
1.34 ± 
1.26
0.29 ± 
0.10
Tumor total area 
(Stumor), cm2
0.55 ± 
0.53
0.3 ± 0.27 0.45 ± 
0.42
0.45 ± 
0.42
0.20 ± 
0.18
Notes: *p<0.05 compared to DMH-treated rats.
The reduction of the total area by 46; 40; 42 and 
54% comparing to DMH group (group 2), was ob-
served in DMH+D1 27-week-treated rats (group 3), 
DMH+D1 7 weeks-treated rats (group 4), DMH+5-
FU-treated rats (group 5) and DMH+D1+5-FU-
treated rats (group 6), respectively (Table 1). The 
decrease in the tumor number by 25; 41; 50 and 
46% comparing to DMH group (group 2), was found 
in DMH+D1 27-week-treated rats (group 4), DMH+D1 7 
weeks-treated rats (group 3), DMH+5-FU-treated rats 
(group 5) and DMH+D1+5-FU-treated rats (group 6), 
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respectively. The reduction of the tumor mean area, 
as compared to the DMH group, in the above groups 
did not reach statistical significance. Thus, anti-
tumor effects of D1 and 5-FU are similar. Notably, 
in DMH+D1 7 weeks- treated rats anti-tumor action 
is stronger comparing to DMH+D1 27 weeks group. 
In group 6, during the concomitant action of D1 and 
5-FU, the effects of the agents are not summed up.
Light microscopy examination of the colon mucosa 
of all treated groups showed the inflammatory features 
in group DMH, manifested by infiltration of lymphocytes 
and histiocytes and blood capillary dilation. Crypts 
inlets sometimes were expanded possibly through 
hyperinflation from mucus check-valve mechanism. 
In groups DMH+D1 7 weeks and DMH+D1 27 weeks, 
inflammatory features were much less pronounced, 
as lower local lymphocytic-histiocytic aggregations 
in group 4 and no changes in group 3 were observed 
comparing to control. On the contrary, the inflamma-
tion was enhanced in group DMH+5-FU, as the infiltra-
tion of lymphocytes and histiocytes was more prevalent 
and the vessel dilations were more frequent. Damage 
of surface epithelium was also observed. Inflammatory 
features in colon mucosa of DMH+D1+5-FU animals 
were manifested more than in groups 3 and 4, but 
somewhat less than in group 5 (Fig. 3).
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Fig. 3. Microphotographs of apparently healthy colon mucosa; hematoxylin-eosine-orange stain; magnification x400. a — group 1; b — 
group 2; c — group 3; d — group 4; e — group 5; f — group 6. Inflammatory features in groups 2; 5; 6 are manifested by infiltration of lym-
phocytes and histiocytes (red arrows) and blood capillary dilation (green arrows). Damage of surface epithelium appears in groups 5 and 6
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Light microscopy also revealed a decrease 
of MI сomparing to DMH group by 30.1%, 35.2% and 
25.5% in DMH+D1 27 weeks-treated, DMH+5-FU-
treated and DMH+D1+5-FU-treated groups, respectively 
(Table 2). Statistically significant changes of CFI between 
groups were not observed. Thus, a reduction of MI com-
paring to DMH group was observed in all test groups 
except of DMH+D1 7 weeks treated rats. Analysis of other 
mucosa parameters (Table 3) showed an increase of the 
mucosa thickness, the height of colonocytes and their 
nuclei area in animals of DMH group (group 2) com-
pared to control. All these parameters were decreased 
by D1 acting for 7 weeks (group 4), whereas only the 
height of colonocytes and their nuclei area were reduced 
by D1 acting for 27 weeks (group 3). Moreover, in the rats 
of group 3, the mucosa thickness and the area of goblet 
cells were increased compared to both the control and 
DMH animals (group 2), which could be explained by in-
creased mucus formation to provide protection against 
xenobiotic [16]. In DMH+5-FU animals (group 5), a de-
crease of the height of colonocytes, no changes in their 
nuclei area and an increase of the mucosa thickness 
compared to DMH ones (group 2) were found. Changes 
of mucosa morphometrial parameters of DMH+D1+5-
FU-treated animals (group 6) could evidence that effects 
of D1 and 5-FU on the conditions of apparently healthy 
mucosa are summed up.
Table 2. Proliferative activity parameters of apparently healthy colonic 
mucosa for rats treated by D1, 5-FU and their combination under DMH-in-
duced carcinogenesis (27 weeks) (Mean ± SEM, n = 10)
MI, % CFI, %
Control 4.25 ± 0.32 9.70 ±1.21
DMH 4.20 ± 0.26 9.84 ± 1.73
DMH+D1 (27 weeks) 3.03 ± 0.24*# 9.32 ± 1.22
DMH+D1 (7 weeks) 3.70 ± 0.35 8.34 ± 1.29
DMH+5-FU 2.87 ± 0.23*# 8.67 ± 1.07
DMH +D1+5-FU 3.18 ± 0.38*# 9.84 ± 1.92
Notes: *p<0.05 compared to control, #p<0.05 compared to DMH.
Table 3. Parameters of apparently healthy colon mucosa for rats trea ted 
by D1, 5-FU and their combination under DMH-induced carcinogenesis 
(27 weeks) (Mean ± SEM, n =10).
Mucosa thick-
ness, μm
Colonocytes 
height, μm
Colonocytes 
nuclei area, 
μm2
Goblet cells 
area, μm2
Control 210.64±9.62 16.75±0.87 14.93±1.22 107.08±11.3
DMH 238.56±11.64* 20.93±1.18* 18.59±1.03* 108.01±9.27
DMH + 
D1 (27 weeks)
257.97±11.64*# 18.60±0.88*# 14.60±1.08# 130.63±14.29*#
DMH + 
D1 (7 weeks)
209.48±9.35# 19.05±0.84* 15.80±0.81# 99.96±6.72
DMH + 5-FU 282.65±12.95*# 18.47±0.7*# 18.08±1.11* 100.91±6.78
DMH + D1 + 
5-FU
239.93±11.44* 17.91±0.64*# 15.40±1.53# 97.12±6.17
Notes: *p<0.05 compared with control, #p<0.05 compared with DMH.
Correlation coefficients between MI and CFI in the 
apparently healthy colon mucosa were calculated 
as 0.13, -0.54 and 0.41 in all, DMH+D1-treated and 
DMH+5-FU+D1-treated rats, respectively. Correlation 
coefficients between Ntumor and Stumor and characteris-
tics of surrounding apparently healthy colon mucosa 
are presented in Table 4.
DISCUSSION
The rats from the DMH-induced cancer groups 
exhibited tumor localization mainly in the distal colon. 
The observed tumors were mainly exophytic, which 
is in good agreement with [15, 17, 18]. It was found that 
D1, 5-FU and their combination mainly affect the growth 
of exophytic tumors (adenomas and hyperplastic polyps) 
(Table 1), which can be explained by peculiarities of the 
development of tumors with different types of growth [17, 
19, 20]. The main proliferation abnormality both in the 
hyperplastic polyps and adenomas appears to be an in-
crease in the rate of crypt fission, a process that begins 
by basal bifurcation and is followed by longitudinal divi-
sion of the crypt, with no changes in the proliferation 
(mitotic) index. However, in adenocarcinomas, prolifera-
tive index in the top zone of the crypt is higher compared 
to adenomas and adenomatous polyps.
D1 causes greater antitumor effect in case of the 
7-week treatment compared to the 27-week one, 
which could be due to adaptation to D1 under its 
prolonged influence, but this certainly warrants more 
detailed further investigation.
Light microscopy examination of the apparently 
healthy colon mucosa of all treated groups showed 
less impact of D1 on the mucosa vascular bed and 
on proliferative activity in comparison with 5-FU, when 
both compounds act for the same duration. The effect 
of D1 is compounded with time exposure increasing 
(27 vs. 7 weeks), but remains less aggressive com-
pared with 5-FU. It points out at the good toxicity profile 
of D1, which constitutes an important common feature 
of the targeted therapies safety [7].
Observed low correlation between MI and CFI 
of healthy mucosa reveals independence of crypt fission 
and cell proliferation processes, which agrees with the 
data of H.S. Park et al. [21, 22]. The correlation between 
MI and the tumor growth parameters was expected 
[17, 22, 23], as the latter is always characterized by the 
increased cell proliferation. The colon adenomas are cha-
racterized by more intensive cell proliferation assessed 
as a number of mitotic cells per one crypt. Thereat, 
proliferated cells are distributed along the whole length 
of the crypts, up to their upper parts, whereas, in normal 
mucosa, they reside only in the lower two-thirds of the 
crypts. Notably, adenocarcinomas are specifically char-
acterized by intensive cell proliferation in the upper parts 
of the crypts and/or in the superficial epithelial layers.
Table 4. Spearman correlation coefficients (rho) between parameters 
of tumor growth (Ntumor and Stumor) and surrounding colon mucosa (MI and 
CFI) for rats treated by D1, 5-FU and their combination under DMH-in-
duced carcinogenesis (27 weeks)
MI CFI
All Ntumor 0.41
Stumor 0.45
DMH Ntumor 0.76 0.63
Stumor 0.77
DMH+5-FU Ntumor 0.5
Stumor -0.3 -0.73
DMH+D1 Ntumor -0.35
Stumor
DMH+D1+5-FU Ntumor -0.32
Stumor -0.41
Note: only statistically significant values are provided.
We analyzed the correlation between parameters 
of colon mucosa and tumor growth in experimental 
groups separately and revealed the difference in the 
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relationships of these parameters. In DMH-treated rats, 
MI strongly correlates with parameters of tumor growth 
and also CFI correlates with Ntumor, which is in agreement 
with data of H.S. Park et al. [21], W.M. Wong et al. [17], 
and S.J. Alrawi et al. [18], and supports the mechanism 
suggesting that the growth of adenomas and adenocar-
cinomas occurs mainly through the crypt fission [24].
Correlation of MI with Ntumor in DMH+5-FU-treated 
rats may indicate the mechanism of the tumor growth 
inhibition by 5-FU as an inhibition of cell proliferation [4]. 
Taking into account a decrease of MI and CFI under the 
influence of 5-FU, negative correlation of MI and CFI 
with Stumor can be explained by the initial increase of crypt 
fission at the tumor growth initiation with its subsequent 
reduction to ensure the cell settlement of newly formed 
crypts under conditions of inhibited proliferation [23].
The decrease of Ntumor and Stumor by D1 in DMH+D1-
treated animals was observed, whereas no correlation 
between MI and parameters of tumor growth was 
found. The lack of correlation could be explained 
by suggestion that D1 mainly acts on transformed cells 
without affecting normal cells proliferation.
Positive correlation between MI and CFI, as well 
as negative correlations between MI and Ntumor and 
between CFI and Stumor observed in DMH+5-FU+D1-
treated rats indicate the difference in mechanisms 
of combined and separate action of D1 and 5-FU, 
which requires further investigation.
So, in conclusion, antitumor effects of D1 (5-amy-
no-4-(1,3-benzothyazol-2-yn)-1-(3-methoxyphenyl)-
1,2-dihydro-3Н-pyrrol-3-one) and 5-FU are similar, 
indicating the effectiveness of D1 as anti-neoplastic 
agent. D1 causes greater antitumor effect in case 
of 7 weeks treatment compared with 27 weeks treat-
ment, which may be explained by adaptation to D1 un-
der its prolonged influence. Impact of D1 on vascular 
bed and proliferative activity of surrounding healthy co-
lon mucosa is gentlier compared with 5-FU. Changes 
in proliferative activity of surrounding healthy colon 
mucosa correlate with tumor growth parameters. The 
correlations between parameters of tumor growth 
and proliferative activity are different in the presence 
of either D1 or 5-FU indicating different mechanisms 
of action and different targets of these compounds.
Obtained results could be useful for better under-
standing of the processes occurring prior to malignant 
transformation of the colon epithelial cells and for their 
pharmaceutical correction.
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